CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-19 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-05-19 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $75.69 | $265K | 153,902 |
| 2026-05-19 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 47,886 | ||
| 2026-05-14 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $77.92 | $584K | 400,330 |
| 2026-05-05 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-05-05 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $77.37 | $271K | 153,902 |
| 2026-05-05 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 51,386 | ||
| 2026-05-05 | WIERENGA WENDELL Director | Option exercise 10b5-1 | +4,032 | $12.40 | $50K | 36,669 |
| 2026-05-05 | WIERENGA WENDELL Director | Sale 10b5-1 | −4,032 | $75.00 | $302K | 32,637 |
| 2026-05-05 | WIERENGA WENDELL Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −4,032 | 0 | ||
| 2026-05-05 | Lee Sung EVP, Chief Financial Officer | Sale 10b5-1 | −23,906 | $76.87 | $1.8M | 63,221 |
| 2026-05-05 | HENDERSON JOHN T Director | Option exercise 10b5-1 | +20,000 | $7.61 | $152K | 95,237 |
| 2026-05-05 | HENDERSON JOHN T Director | Sale 10b5-1 | −20,000 | $75.97 | $1.5M | 75,237 |
| 2026-05-05 | HENDERSON JOHN T Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −20,000 | 0 | ||
| 2026-05-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +11,333 | $39.13 | $443K | 69,888 |
| 2026-05-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −11,333 | $77.25 | $875K | 58,555 |
| 2026-05-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −11,333 | 13,070 | ||
| 2026-05-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,857 | $37.63 | $597K | 74,412 |
| 2026-05-01 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,857 | $65.00 | $1.0M | 58,555 |
| 2026-05-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,857 | 0 |
Page 8 of 22 · 429 trades